

parsimoniously place it with the other reduplications (place, time, body parts), all of which can be localized to the non-dominant parietal cortex—rather than with the agnosias, which can be associated with various cortical dysfunctions according to the sensory modality affected.

RICHARD ABRAMS

*Department of Psychiatry & Behavioural Sciences,
University of Health Sciences,
The Chicago Medical School,
VA Hospital, Bldg 50,
North Chicago, Illinois 60064*

REFERENCES

1. HAYMAN, M. A. & ABRAMS, R. (1977) Capgras' syndrome and cerebral dysfunction. *Brit. J. Psychiat.*, 130, 68–71.
2. WEINSTEIN, E. A. & KAHN, R. L. (1955) *Denial of Illness*, pp 48–59. Springfield: Chas. C. Thomas.

ELECTROCONVULSIVE THERAPY

DEAR SIR,

I recently treated a 62-year-old professional man with a course of right unilateral ECT. He had made a serious suicidal attempt by overdosage of drugs and had clear-cut signs of endogenous depression and a history of two previous episodes of depression for which psychiatric advice had not been sought.

For about 14 years he has suffered from bilateral nerve deafness and tinnitus. These symptoms followed an illness and were attributed to treatment with streptomycin. Having now maintained a good recovery from his depressive episode for eight weeks, he tells me that his tinnitus is much worse and he associates it with the application of ECT. I have treated with ECT other patients in his age group who have had deafness and tinnitus and have not had this difficulty described to me previously.

I wonder if any other psychiatrists have encountered such a side-effect?

W. J. CHARLES

*Washam Park Hospital,
Kirkham, Preston,
Lancs PR4 3AL*

MOURNING AFTER PETS

DEAR SIR,

I was interested in Dr Keddie's paper (*Journal*, July 1977, pp 21–5). In it he states that 'where such overdependence on a pet does exist there is likely to be a sharp reaction on the part of the owner when the pet dies or has to be "put to sleep" '.

I am at present studying the relationship between children and their dogs. In the results from the 'normal' group, 23 out of 31 parents reported that they had considered the possibility of significant emotional distress occurring (in themselves or the child) if the dog was killed or otherwise permanently lost. This was a factor in their choice of pet, and is statistically significant ($P < 0.05$; binomial test, two tailed, corrected for continuity). This suggests that a certain amount of distress is anticipated by the general public at the loss of a pet dog. The mourning described by Dr Keddie is therefore pathological in severity rather than occurrence, and is presumably related to the degree of overdependence, as he implies in his paper. However, degrees of mourning for dogs may be more widespread in the community than has been thought.

A. J. MACDONALD

*University Department of Psychiatry,
Ninewells Hospital,
Dundee DD2 1UD*

LITHIUM INGESTION IN THE POPULATION

DEAR SIR,

At the recent first British Lithium Symposium at Lancaster University, Dr A. I. M. Glen reported that in Edinburgh one citizen in every thousand was regularly taking lithium. In the closing address, Dr R. P. Hullin of Leeds reported, as the result of a broad survey, that nationwide about one in two thousand were on lithium treatment.

The biochemistry laboratory at Crichton Royal has the monopoly of measurement of plasma Li levels from patients resident within South West Scotland, a relatively self-contained area with minimal population mobility. As at 25 July 1977 there were 113 residents of the area receiving lithium therapy, comprising 93 out-patients, 18 longer-stay in-patients and psychogeriatric day-patients, and 2 recent admissions. From a population of 150,000 the figures reveal that one in every 1,330 persons is receiving lithium therapy.

J. C. LITTLE

*Department of Clinical Research,
Crichton Royal,
Dumfries DG1 4TG*

PLATELET MAO IN SCHIZOPHRENICS
WITH AND WITHOUT FAMILY HISTORY
OF SCHIZOPHRENIA

DEAR SIR,

We recently reported (1) that we were unable to confirm the findings of Murphy and Wyatt (2) of

low platelet monoamine oxidase (MAO) in schizophrenia. Since that study numerous reports have appeared on platelet MAO in schizophrenia, some able (3, 4, 5) and others unable (6, 7) to confirm the original report of Murphy and Wyatt (2). Since low platelet MAO has been suggested as a genetic marker for vulnerability to schizophrenia (8) it seemed that non-genetic 'phenocopies' of schizophrenia would be expected to lack the marker of low platelet MAO. Since schizophrenia is thought to be heterogeneous in aetiology, it seemed possible that non-genetic phenocopies of schizophrenia without low platelet MAO may be over-represented in studies that find platelet MAO normal in schizophrenia. This might explain the discrepant findings between studies.

To test this hypothesis we evaluated 34 chronic schizophrenic in-patients at the Jerusalem Mental Health Centre. Overlap with the previous study was minimal and diagnostic criteria were identical (1). Eleven patients were determined by case paper review and interview of relatives to have a first-degree relative with schizophrenia; ten patients were determined to have no family history of schizophrenia whatsoever. Thirteen patients had a family relative with a mental illness questionably schizophrenia or a schizophrenic family relative more distantly related than the first degree; these were excluded from the study. A normal control group was selected from hospital employees with no history of mental illness.

Platelet MAO was measured using benzylamine as substrate, as described previously (1). The Table

TABLE
Platelet MAO in schizophrenics with and without family history of schizophrenia

Group	N	Sex	Age	Platelet MAO (nanomoles/hr/mg protein)
Schizophrenics with first-degree schizophrenic relatives	11	8M 3F	26.6 (18-38)	49.9 ± 16.0 (32-87)
Schizophrenics with no family history of mental illness	10	7M 3F	32.2 (23-39)	51.0 ± 20.2 (17-86)
Normal controls	12	7M 5F	29.8 (17-43)	44.8 ± 14.5 (23.71)

shows platelet MAO in schizophrenic patients with and without a first-degree relative with schizophrenia and in the normal controls. The results show no difference in platelet MAO between the 'more genetic' and 'less genetic' groups of schizophrenic patients. Moreover, the results are identical with our previous study, which found platelet MAO slightly, but not significantly, higher in schizophrenic patients than in normal controls (1). Thus presence or absence of non-genetic phenocopies for schizophrenia cannot explain the discrepant results in the literature.

ROBERT H. BELMAKER
AVI GALON
LEON PERÉZ
RICHARD EBSTEIN

POB 140,
Jerusalem Mental Health Centre,
Jerusalem, Israel

REFERENCES

- BELMAKER, R. H., EBSTEIN, R. P., EBBESEN, K. & RIMON, R. (1976) Platelet monoamine oxidase in schizophrenia and manic-depressive illness. *Brit. J. Psychiat.*, **129**, 227-9.
- MURPHY, D. L. & WYATT, R. J. (1972) Reduced MAO activity in blood platelets from schizophrenic patients. *Nature*, **238**, 225-6.
- MELTZER, H. Y. & STAHL, S. M. (1974) Platelet monoamine oxidase activity and substrate preferences in schizophrenic patients. *Res. Comm. in Chem. Path. Pharmacol.*, **7**, 419.
- DOMINO, E. F. & KHANNA, S. S. (1976) Decreased blood platelet MAO activity in unmedicated chronic schizophrenic patients. *Amer. J. Psychiat.*, **133**, 323-6.
- ZELLER, E. A., BOSHES, B., DAVIS, J. M. & THORNER, M. (1975) Molecular aberration in platelet MAO in schizophrenia. *Lancet*, *i*, 1385.
- FRIEDMAN, E., SHOPSIN, B., SANTHANANTHAN, G. & GERSHON, S. (1974) Blood platelet MAO activity in psychiatric patients. *Amer. J. Psychiat.*, **131**, 1392-4.
- OWEN, F., BOURNE, R., CROW, T. J., JOHNSTONE, E. L., BAILEY, A. R. & HERSHON, H. J. (1976) Platelet MAO in schizophrenia. *Arch. gen. Psychiat.*, **33**, 1370-3.
- WYATT, R. J., MURPHY, D. L., BELMAKER, R. H., COHEN, S., DONNELLY, C. H. & PELLIN, W. (1973) Reduced monoamine oxidase in platelets: a possible genetic marker for vulnerability to schizophrenia. *Science*, **179**, 916-18.